250 Users Online
Rheumatoid Arthritis Treatment Market Segmented By Symptomatic Treatment, Intermediate Corticosteroid Therapies, and Conventional DMARDs, Biologic DMARDs as Disease Modifying Antirheumatic Drug Therapies in Hospital Pharmacy, Retail Pharmacy, Drug Stores
The global revenue from the rheumatoid arthritis treatment market stands at US$ 42.9 Bn in 2022, with the global market expected to grow at a CAGR of 5.7% to reach a valuation of approximately US$ 79.1 Bn by the end of 2033.
Market Size (2022)
US$ 42.9 Bn
Projected Market Value (2033)
US$ 79.1 Bn
Global Market Growth Rate (2023-2033)
Market Share of Top 4 Countries
As assessed by Persistence Market Research, disease modifying anti-rheumatic drug (DMARD) therapy holds a market share of around 88.3% in 2022. Overall, rheumatoid arthritis treatment market sales account for approximately 43.1% revenue share in the global anti-inflammatory therapeutics market, which was valued at around US$ 99.6 Bn in 2022.
The global market recorded a historic CAGR of 5.8% in the last 56 years from 2016 to 2022.
Rheumatoid arthritis (RA) is a complex inflammatory disease with an unclear aetiology that usually affects the joints but can also show extra-articularly. Good RA care necessitates a multidisciplinary approach because of its complexity, which itself is predicated on a pathophysiological process that remains partly recognized.
Due to breakthroughs in treatment and diagnosis that have made it conceivable to reduce clinical symptoms and prevent systemic complications, the clinical status of RA patients has improved in recent years. The development of disease-modifying anti-rheumatic drugs (DMARDs), which include traditional synthetic, biologic, and customized synthetic treatments, has yielded the most promising outcomes.
Additionally, ongoing drug development has revealed molecules with enhanced safety and efficacy profiles. However, more research is necessary before RA could become a pathology that may be cured.
New therapeutic techniques are now available as a result of significant advancements in the pharmaceutical industry. Finding a cure, however, is difficult considering the limited comprehension of the molecular processes that control how antibodies respond.
The best therapeutic strategy calls for an early diagnosis, the optimal non-pharmacological and pharmacological therapies, as well as regular assessments of therapeutic efficacy and safety. The goals of treatment are to achieve remission and minimise negative effects.
The American College of Rheumatology has developed a new class of nonbiologic DMARDs, which comprises targeted synthetic disease-modifying antirheumatic drugs, biologic DMARDs, and conventional synthetic DMARDs that help maintain joint function.
The market for rheumatoid arthritis treatment is being driven by a rise in the prevalence of arthritis and related joint issues. An unhealthy lifestyle, increasing metabolic disorders, ageing, a family history of joint ailments, and growing obesity are all contributing factors to the rise in rheumatoid arthritis. To improve their position in this market, manufacturers are concentrating on working with other market players.
Thus, owed to the above-mentioned factors, the global market is likely to show high growth over the coming years at a CAGR of 5.7% and reach a global market size of US$ 79.1 Bn by 2033.
“High Disease Prevalence in Underdeveloped Regions, Establishment of Regulatory Guidelines, and Emergence of Novel Therapeutics”
In the Middle East and Africa, rheumatoid arthritis is one of the main causes of disability. The prevalence of RA is estimated to be 0.3% in Egypt and 0.4% in Lesotho, according to a comprehensive review and meta-analysis on the subject published by Stellenbosch University in South Africa.
In light of Africa's underdeveloped but rapidly expanding economy, generic players have enormous growth potential there.
The expansion of the generic market is anticipated to come from a number of specific nations, primarily as a result of the adoption of the Substitution Law in South Africa and Nigeria, the growing purchasing power of the Moroccan government, and other factors.
Various laws established in the past few years have changed how regulatory review and clinical development are conducted in the United States over time.
The Food and Drug Administration Safety and Innovation Act of 2012 introduces a new platform designation of a breakthrough therapy-to guarantee prompt access to medications for uncommon and deadly diseases.
In order to ensure that patients have access to the medications they need on a priority basis and to address the difficulties associated with growing the global drug supply chain, the act incorporates a number of provisions.
The act also permits manufacturers to apply for fast-track approval, which saves time and effort for the FDA and drug manufacturers, and it promotes companies to develop novel solutions.
Additionally, mesenchymal stem/stromal cell (MSC)-based cell therapy is an attractive novel strategy to address persistent treatment issues for RA patients. The ability of MSCs to self-renew and regenerate tissues and organs initially sparked interest in the subject of MSCs. MSC therapies then expanded their therapeutic value to chronic inflammatory diseases due to their immunomodulatory characteristics.
Emergence of novel treatment modalities is thus set to present the market with lucrative opportunities for expansion during the forecast period.
“Cost Limitations on Existing Treatment Options and Limited Insurance Coverage”
Two out of three patients respond to biologic treatments for rheumatoid arthritis, which are outperforming traditional DMARDs in this regard. The monthly cost of these medications, however, can range from US$ 1,000 to US$ 3000. Even if the patient has an excellent health insurance plan, it may not always cover biologics, thus the out-of-pocket costs are excessive.
Thus, the main barrier limiting the rate of treatment with biologics and, consequently, limiting market growth is the high cost of treatment.
The cost of Humira has increased from approximately $19,000 per year (in 2012) to more than $38,000 per year (in 2019), according to the Institute for Clinical and Economic Review, 2021.
Rheumatoid arthritis symptoms vary widely across patients, regardless of age, maturity level of disease onset, etc., which is one of the reasons for the high cost. For instance, according to survey results from Medlink U.K., 75% of RA patients experience a range of symptoms such joint pain, swelling, and flare-ups, 20% have relatively mild cases of the disease, and just 5% progress to a severe form with deformities.
The extensive treatment necessitated by these 5% of patients, who exhibit very little activity, contributes for the significant expense of the treatment. The burden on the government from these 5% of patients in Europe is around US$ 5.2 billion annually.
Thus, high costs associated with treatment are set to restrict the growth of the overall market over the forecasted years.
Why is the U.S. Market Booming?
“Rising Disease Prevalence and Rising Government Investments”
The U.S. is set to account for around 39.8% share in the global market in 2023. According to the Centers for Disease Control and Prevention, 58.5 million Americans, or about one in four, have arthritis.
In addition, factors such as the rise in rheumatoid arthritis prevalence, the rapid uptake of disease-modifying antirheumatic drugs (DMARDs), accessibility of cutting-edge healthcare facilities with qualified medical staff, the rise in R&D activities, and the rapid increase in government investments in the healthcare system are expected to further drive the market's expansion over the forecast period.
Will Germany Be a Lucrative Market for Rheumatoid Arthritis Treatment?
“Growing Pharmaceutical Industry and Rising R&D Investments”
Germany is set to hold around 9.0% share of the global market in 2023.
The considerable prevalence of many rheumatic disorders in different countries around the region is one of the main reasons fuelling market expansion. Furthermore, it is expected that one of the major drivers boosting market expansion throughout the course of the projected period will be the existence of an innovative and growing pharmaceutical industry in the major European nations.
The chances for the market to grow in the upcoming years are being further expanded by the region's rising investments in pharmaceutical R&D.
How is Japan Emerging as a Prominent Market?
“Implementation of Health Technology Assessment Programme to Address High Drug Pricing”
Japan is set to hold a market share of about 5.4% of the global market in 2023.
The increasingly ageing population and rising numbers of people living with chronic diseases who need continuous medical care are both contributing to Japan's rising health and pharmaceutical costs. In response to problems with drug pricing in Japan, the government implemented health technology assessment (HTA) as a trial programme in April 2016 with the overt political goal of enhancing drug price regulation.
The comparator method, in which the comparator is chosen from the most current comparable pharmaceuticals registered under National Health Insurance, is the fundamental pricing strategy for new drugs (NHI). When there are no comparable medications on the NHI list, a cost calculation method is utilised as an exception.
Considerations to drug pricing aim towards the cost reduction for treatment of rheumatoid arthritis, thus promoting Japan as a lucrative market during the forecast period.
Which Treatment is Driving Demand within the Global Market?
“High Efficacy in Prevention of Disease Progression”
Disease modifying anti-rheumatic drug (DMARD) held around 88.3% of the total market in 2022. People with rheumatoid arthritis frequently use a class of pharmaceuticals known as disease-modifying antirheumatic drugs (DMARDs). Ankylosing spondylitis, psoriatic arthritis, and systemic lupus erythematosus are among the various ailments that some of these drugs are used to treat.
Inflammatory forms of arthritis are treated with disease-modifying antirheumatic medications that stop or delay the progression of the disease. By reducing inflammation, DMARDs support the preservation of joints. Without DMARDs, chronic inflammation would gradually erode the joint tissues over time.
Which Distribution Channel Provides the Global Market With a Large Share?
“Greater Patient Adherence with Outpatients”
The hospital pharmacy segment held a share of about 83.8% in 2022. The complexity of the drug may have an impact on non-adherence, although RA often necessitates lifelong treatment. In outpatients with chronic conditions, pharmacist-led telehealth services are as effective as in-person care and reduced potential side effects.
Pharmacists provide patients with standardized and individualized pharmaceutical services in order to better meet their requirements for prescription counselling and to increase adherence and therapeutic effectiveness. Owed to these factors, the hospital pharmacy segment holds a greater share within the global market.
The main participants in the global market for rheumatoid arthritis treatment generally employ co-commercialization and distribution partnerships as marketing and distribution strategies.
Throughout the anticipated period, the introduction of novel JAK inhibitors for rheumatoid arthritis will stimulate market growth.
Some key instances of development within the market include:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the rheumatoid arthritis treatment market, which are available in the full report.
Historical Data Available for
USD Million for Value
Key Countries Covered
Key Market Segments Covered
Key Companies Covered
Customization & Pricing
Available upon Request
The global market is currently valued at around US$ 42.9 Bn in 2022.
Sales of the market are set to witness growth at a CAGR of 5.7% and be valued at around US$ 79.1 Bn by 2033.
Demand for the global market increased at a 5.8% CAGR from 2016 to 2022.
The U.S., Germany, Japan, and Australia account for most demand within the market, currently holding around 55.2% market share.
The U.S. is set to account for around 39.8% share of the global market in 2023.
Europe is set to account for more than 25% share of the global market in 2023.
Japan market is set to hold a share of about 5.4% in the global market in 2023.
Germany is set to hold around 9.0% share of the global market in 2023.
China market is expected to grow at 9.8% CAGR during the forecast period.
The market in India is set to expand at a 9.2% CAGR over the forecast period.